Erschienen in:
01.10.2015 | Editorial
Chemoprevention of Post-ERCP Pancreatitis with Rectal NSAIDs: Does Poking Both Ends Justify the Means?
verfasst von:
Tilak Shah, Alvin Zfass, Mitchell L. Schubert
Erschienen in:
Digestive Diseases and Sciences
|
Ausgabe 10/2015
Einloggen, um Zugang zu erhalten
Excerpt
Acute pancreatitis, the most common severe complication of endoscopic retrograde cholangiopancreatography (ERCP), accounts for up to 50 % of all ERCP-related lawsuits. The overall incidence of post-ERCP pancreatitis (PEP) is 1.6–15 % [
1]. Yet, the likelihood of developing this complication is several-fold higher in patients with risk factors such as female gender, pre-cut papillotomy, endoscopic sphincterotomy, suspected sphincter of Oddi dysfunction, and previous PEP [
2]. In patients with multiple risk factors, the incidence of pancreatitis after ERCP may be as high as 30–40 % [
1]. …